Citadel Advisors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Citadel Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-22,300	Closed	-$780K	–	15897
2024 Q1	$780K	Sell	22,300 -74,700	-77%	-$2.72M	﹤0.01%	7447
2023 Q4	$3.69M	Buy	97,000 +94,100	+3,245%	+$2.02M	﹤0.01%	4283
2023 Q3	$53.2K	Sell	2,900 -700	-19%	-$14.6K	﹤0.01%	11689
2023 Q2	$93.5K	Sell	3,600 -2,300	-39%	-$53.7K	﹤0.01%	11037
2023 Q1	$111K	Sell	5,900 -2,800	-32%	-$65.1K	﹤0.01%	11098
2022 Q4	$214K	Buy	+8,700	New	+$256K	﹤0.01%	9995
2022 Q3	–	Sell	-21,600	Closed	-$245K	–	14350
2022 Q2	$245K	Sell	21,600 -10,900	-34%	-$160K	﹤0.01%	10265
2022 Q1	$724K	Buy	32,500 +6,800	+26%	+$174K	﹤0.01%	8489
2021 Q4	$1.12M	Buy	+25,700	New	+$1.03M	﹤0.01%	7675

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's INBX Position: Q2 2024 in Review

Citadel Advisors sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 1,204,252 shares — an estimated $42.1M sold.

Citadel Advisors first reported a position in INBX in Q4 2021 and held it in 10 quarters. The position peaked at $42.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Citadel Advisors reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 1,204,252 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $42.1M.
Citadel Advisors first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
Citadel Advisors's Inhibrx, Inc. Common Stock position peaked at $42.1M in Q1 2024.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.